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Abstract
β-Thalassemias are extremely heterogeneous at the molecular level.  More than 200
disease-causing mutations have been identified. The majority of mutations are single
nucleotide substitutions. Rarely, β-thalassemia results from gross gene deletion. The
degree of globin chain imbalance is determined by the nature of the mutation of the β-
gene. β0 refers to the complete absence of production of β-globin on the affected allele.
β+ refers to alleles with some residual production of β-globin (around 10%). In β++, the
reduction in β-globin production is very mild. The broad spectrum of β-thalassemia
alleles can produce a wide spectrum of different β-thalassemia phenotypes. In this
chapter, we review the molecular basis of the marked heterogeneity of the thalassemia
syndromes or in other words the genotype-phenotype relationship in β-thalassemia.
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1. Introduction
β-Thalassemia syndromes are a group of hereditary blood disorders characterized by reduced
or  absent  β-globin  chain  synthesis,  resulting  in  reduced  Hb  in  red  blood  cells  (RBCs),
decreased RBC production, and anemia. β-Thalassemia includes three main forms: Thalas-
semia  Major,  variably  referred  to  as  “Cooley’s  Anemia”  and  “Mediterranean  Anemia,”
Thalassemia Intermedia,  and Thalassemia Minor also called “β-thalassemia carrier,” “ β-
thalassemia trait,” or “heterozygous β-thalassemia” [1].
The β-thalassemia syndromes are much more diverse than the α-thalassemia syndromes due
to the diversity of the mutations that produce the defects in the β-globin gene. The severity of
β-thalassemia relates to the degree of imbalance between the α- and non-α-globin chains. The
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β-globin gene maps in the short arm of chromosome 11, in a region that contains also the delta
globin gene, the embryonic epsilon gene, the fetal gamma genes, and a pseudogene (ψB1) [1].
Unlike the deletions that constitute most of the α-thalassemia syndromes, β-thalassemias are
caused by hundreds of mutations that affect all aspects of β-globin production: transcription,
translation, and the stability of the β-globin product [2].
2. Classification of β-thalassemias
1. β-Thalassemia
• Thalassemia major
• Thalassemia intermediate
• Thalassemia minor
2. β-Thalassemia with associated Hb anomalies
• HbC/β-thalassemia
• HbE/β-thalassemia
• HbS/β-thalassemia
3. Hereditary persistence of fetal Hb and β-thalassemia
4. Autosomal dominant forms of β-thalassemia
5. β-Thalassemia associated with other manifestations
• β-Thalassemia-trichothiodystrophy
• X-linked thrombocytopenia with thalassemia
2.1. Epidemiology of β-thalassemias
The frequency of β-thalassemia varies widely, depending on the ethnic population. The disease
is reported most commonly in Mediterranean, African, and Southeast Asian populations. The
highest carrier frequency is reported in Cyprus (14%), Sardinia (10.3%), and Southeast Asia [1].
Population migration and intermarriage between different ethnicities have introduced
thalassemia in almost every country of the world, including Northern Europe, where thalas-
semia was previously absent [2].
About 1.5% of the global population (80–90 million) are β-thalassemia carriers, with about
60,000 symptomatic individuals born annually. Incidence of symptomatic individuals is
estimated at 1 in 100,000 worldwide and 1 in 10,000 in Europe [2].
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It is the most common chronic hemolytic anemia in Egypt (85.1%), and its carrier rate has been
estimated at 9–10.2% from an examination of 1000 normal random subjects from different
geographic areas of the country [3].
2.2. Etiology of β-thalassemia
β-Thalassemia is inherited as an autosomal recessive disorder. There are hundreds of muta-
tions within the β-globin gene, but approximately 20 different alleles comprise 80% of the
mutations found worldwide. Within each geographic population, there are unique mutations.
The large majority of mutations are point mutations. Deletions of β-globin gene are uncom-
mon. Mutations in β-globin gene cause a reduced or absent production of the β-globin chains
[4]. Table 1 displays the list of common mutations according to severity and ethnic distribution.
β-Gene mutation Ethnicity Severity
−619 del Indian β0
−101 C→T Mediterranean β++
−88 C→T Black β++
−87 C→G Mediterranean, African β++
−31 A→G Japanese β++
−29 A→G African β++
−28 A→C Southeast Asian β++
IVS1-nt1 G→A Mediterranean, Asian Indian β0
IVS1-nt5 G→C East Asian, Asian Indian β0
IVS1-nt6 T→C Mediterranean β+/++
IVS1-nt110 G→A Mediterranean β+
IVS2-nt654 C→T Chinese β+
IVS2-nt745 C→G Mediterranean β+
Codon 39 C→T Mediterranean β0
Codon 5 -CT Mediterranean β0
Codon 6 -A Mediterranean, African-American β0
Codon 41/42 -TTCT Southeast Asian β0
AATAAA to AACAAA African-American β++
AATAAA to AATGAA Mediterranean β++
Codon 27 G→T Hb (Hb Knossos) Mediterranean β++
Codon 79 G>A (Hb E) Southeast Asian β++
Codon 19 G>A (Hb Malay) Malaysian
Table 1. Common mutations of β-thalassemia according to severity and ethnicity.
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3. Genotype phenotype relationship in β-thalassemia
Mutations causing thalassemia can affect any step in the pathway of globin gene expression.
The most common forms arise from mutations that derange splicing of the mRNA precursors
or prematurely terminate translation of the mRNA. The resulting phenotype reflect the effects
of the β0 thalassemia in which there is no B-globin gene production and B+, B++ thalassemia in
which there is marked or mild reduction in production of β-chain [5].
3.1. Genetic modifiers
Several modifier genes have been identified which are able to influence the severity of β-
thalassemia, so at phenotypic level β-thalassemias are considered multigenic diseases.
Improved understanding of the influence of modifier genes involved in modulating the
complex pathophysiology of β-thalassemia may allow prediction of disease phenotype [6].
3.1.1. Primary modifiers
Primary genetic modifiers in homozygous β-thalassemia include genetic variants able to
reduce the globin chain imbalance, therefore resulting in a milder form of thalassemia.
1. The presence of silent or mild β-thalassemia alleles associated with a high residual output
of β-globin.
2. The coinheritance of α-thalassemia.
3. Genetic determinants able to sustain a continuous production of gamma globin chains
(HbF) in adult life.
3.1.2. Secondary modifiers
The clinical phenotype of homozygous β-thalassemia may also be modified by the coinheri-
tance of other genetic variants mapping outside the globin clusters.
1. TA7 polymorphism in the promoter region of the uridine diphosphate-glucuronosyl
transferase gene is associated with cholelitiasis in thalassemic patients [7].
2. Apolipoprotein Eε4 allele seems to be a genetic risk factor for left ventricular failure in
β-thalassemia [8].
3. Genes involved in iron (i.e., C282Y and H63D HFE gene mutations) and bone metabolism
[9].
4. Glutathione-S-transferase M1 gene polymorphism has been associated with an increased
risk of cardiac iron overload in patients with thalassemia major [10].
5. Excess functional α-globin genes (α gene triplication or quadruplicating) in heterozygous
β-thalassemia may lead to thalassemia intermedia phenotype instead of the asymptomatic
carrier state [11].
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4. Pathophysiology of β-thalassemia
The basic defect in β-thalassemia is a reduced or absent production of β-globin chains with
relative excess of α-chains. Because α- and non-α chains pair with each other at a ratio close
to 1:1 to form normal Hb, the excess unmatched α chains accumulate in the cell as an unstable
product, leading to cell destruction in the bone marrow and in the extramedullary sites. This
process is referred to as ineffective erythropoiesis (IE) and is the hallmark of β-thalassemia [12].
Figure 1. Pathophysiology of β-thalassemia.
The excess α-chains may, in minor amounts, combine with residual β- (in β+ -thalassemia) and
γ-chains (whose synthesis persists usually in small quantity after birth), undergo proteolysis,
or in large part become associated with the erythroid precursors with deleterious effects on
erythroid maturation and survival. Also excess α-chain precipitation in the red cell membrane
causes structural and functional alterations with changes in deformability, stability, and red
cell hydration [12].
Alterations of erythroid precursors result in an enhanced rate of apoptosis, which is a pro-
grammed cell death. Apoptosis could contribute significantly to ineffective erythropoiesis and
occurs primarily at the polychromatophilic erythroblast stage. The ineffective erythropoiesis
(IE) and anemia have several consequences producing the clinical picture of the disease. The
first response to anemia is an increased production of erythropoietin, causing a marked
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erythroid hyperplasia, which may range between 25 and 30 times normal. Anemia may
produce cardiac enlargement and sometimes severe cardiac failure [12].
Increased erythropoietin synthesis may stimulate the formation of extramedullary erythro-
poietic tissue, primarily in the thorax and paraspinal region. Marrow expansion also results
in characteristic deformities of the skull and face, as well as osteopenia [13].
High levels of iron, closely associated with denatured hemoglobin, have been found in the
membrane of β-thalassemic red cells [14].
Severe IE, chronic anemia, and hypoxia also cause increased gastrointestinal (GI) tract iron
absorption. This is combined with increased iron from the breakdown of RBCs and the
increased iron introduced into the circulation by the transfusions necessary to treat thalasse-
mia, plus inadequate excretory pathways lead to progressive deposition of iron in tissues and
hemosiderosis occurs [13].
Free iron species, such as labile plasma iron as well as labile iron pool in the RBCs accumulate
when transferrin saturation exceeds 70%. These free iron species generate reactive oxygen
species with eventual tissue damage, organ dysfunction, and death (Figure 1) [13].
5. Clinical presentation of β-thalassemia
5.1. History
The history in patients with thalassemia widely varies, depending on the severity of the
condition and the age at the time of diagnosis. In most patients with thalassemia traits, no
unusual signs or symptoms are encountered, children with thalassemia major usually present
between 3 months and 1 year of life, and occasionally presentation is delayed to 4−5 years [15].
Some patients, especially those with somewhat more severe forms of the disease, manifest
some pallor and slight icteric discoloration of the sclerae with splenomegaly, leading to slight
enlargement of the abdomen. Thalassemia should be considered in any child with hypochro-
mic microcytic anemia that does not respond to iron supplementation [15].
5.2. Physical
Patients with thalassemia minor are often asymptomatic. They have mild anemia and their Hb
level is usually not less than 9−10 g/dl therefore pallor and splenomegaly are rarely observed.
The stigmata of severe untreated α-thalassemia major included the following:
• Severe anemia, with an Hb level of 3−7 g/dl
• Massive hepatosplenomegaly
• Severe growth retardation
• Bony deformities
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Patients with signs of iron overload may also demonstrate signs of cardiomyopathy and
endocrinopathy caused by iron deposits. Diabetes and thyroid or adrenal disorders have been
described in these patients [16].
6. β-Thalassemia workup
6.1. Laboratory studies
6.1.1. Complete blood count and peripheral blood film examination
In the severe forms of thalassemia, the Hb level ranges from 2 to 8 g/dl. MCV and MCH are
significantly low. Reticulocyte count is elevated to 5–8% and leukocytosis is usually present.
Platelet count is usually normal, unless the spleen is markedly enlarged. Peripheral blood film
examination reveals nucleated RBCs and occasional immature leukocytes.
6.1.2. Hemoglobin electrophoresis
High performance liquid chromatography (HPLC) is now usually used as first-line method to
diagnose hemoglobin disorders. HPLC or hemoglobin electrophoresis reveals absence or
almost complete absence of Hb A, with almost all the circulating hemoglobin being Hb F. The
Hb A2 percentage is normal, low, or slightly raised.
6.1.3. Biochemical studies
1. Serum iron and ferritin: Serum iron level and ferritin levels are elevated. However, an
assessment using serum ferritin levels may underestimate the iron concentration in the
liver. Liver iron concentration (LIC) could be estimated by liver biopsy or T2* MRI, which
provides a noninvasive alternative to liver biopsy. LIC could also monitored by the use of
superconducting quantum interference device (SQUID).
2. Transferrin saturation: Transferrin saturation is a surrogate marker for NTBI [17].
Transferrin saturation >50% is suggestive of a high iron load.
3. NTBI and LPI: NTBI and LPI are very specific for iron overload and can be used to monitor
the response to chelation therapy [18].
4. Hepcidin measurement: Hepcidin can be measured in serum and urine using mass
spectrometry, and this may be a feasible marker in the near future [19].
5. Other biochemical changes: Serum zinc, serum and leucocytic ascorbic acid, vitamin E,
and folic acid are low. LDL is elevated as consequence of ineffective erythropoiesis [20].
6.2. Imaging studies
Findings show skeletal changes, including thinning of the cortex, widening of the medulla,
and coarsening of trabeculations, due to bone marrow hyperplasia in the long bones, meta-
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carpals, and metatarsals. Skull bones show “hair-on-end.” The maxilla may overgrow, which
results in maxillary overbite, prominence of the upper incisors, and separation of the orbit.
These changes contribute to the classic chipmunk facies observed in patients with thalassemia
major [21]. Chest radiography is used to evaluate cardiac size and shape. Left ventricular
function can be quantified using MRI, MUGA (multiple gated acquisition scan) or echocar-
diography [22].
Cardiac T2*, a noninvasive procedure involves measuring the cardiac T2 with cardiac magnetic
resonance (CMR). This procedure has shown decreased values in cardiac T2 due to iron deposit
in the heart. Unlike liver MRI, CMR does not correlate well with the ferritin level, the liver iron
level, or echocardiography findings. The liver is clear of iron loading much earlier than the
heart, and so the decision to stop or reduce chelation treatment based on liver iron levels is
misleading [23].
A poor correlation was noted between cardiac and hepatic iron concentrations as assessed by
T2-MRI where approximately 14% of patients with cardiac iron overload were identified who
had no matched degree of hepatic hemosiderosis [24].
6.3. Molecular genetic analysis
PCR-based procedures can detect the commonly occurring mutations in β-globin gene. The
most commonly used methods are reverse dot blot analysis or primer-specific amplification,
with a set of probes complementary to the most common mutations in each population. β-
Globin gene sequence analysis is used to detect mutations in the β-globin gene in case of failure
of targeted mutation analysis [25].
6.4. Prenatal diagnosis
Prenatal diagnosis is possible through analysis of DNA obtained through chorionic villi
sampling at 8–10 weeks’ fetal gestation or by amniocentesis at 14–20 weeks’ gestation. In most
laboratories, the DNA is amplified using the PCR assay test and then is analyzed for the
presence of the thalassemia mutation using a panel of oligonucleotide probes corresponding
to known thalassemia mutations. Prenatal diagnosis may be performed noninvasively, with
the use of maternal blood samples to isolate either fetal cells or fetal DNA for analysis [26].
7. Treatment of thalassemia
7.1. Transfusion therapy
In general, children with β-thalassemia major and hemoglobins of less than 6–7 g/dl should
receive chronic transfusions. It is important to start early before the child has a chance to
develop splenomegaly and hypersplenism and before skeletal changes and growth retarda-
tion. It is also important to establish a reliable, routine transfusion schedule that maintains
hemoglobin levels of 9–10 g/dl [27].
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Transfusions of washed, leukocyte-depleted RBCs are recommended for all the patients to
reduce the incidence of febrile and urticarial reactions as well as infectious cytomegalovirus
contamination [28]. Extended red cell antigen typing, including at least the Rh antigens, Duffy,
Kidd, and Kell, is recommended before the patient is started on a transfusion regimen [27].
7.2. Iron chelation therapy
Children with thalassemia major should begin therapy at the earliest possible age and certainly
by the time they have accumulated more than 7 g of excess iron. In young children, a serum
ferritin level much greater than 1.000 μg/l or 1 year of regular transfusions (or both) can be
used as surrogate indicators to initiate chelation therapy [27].
7.2.1. Deferoxamine
Deferoxamine (DFO) is a hexadentate iron chelator (deferoxamine mesylate; desferal®). DFO
was introduced as parenteral therapy for iron overload associated with β-thalassemia major
in 1976 [30]. Plasma half-life of DFO is short (20–30 min). Therefore, standard treatment
involves the subcutaneous infusion of 40 mg DFO for 8–12 h nightly for 5–7 nights weekly
using a battery-operated infusion pump. Subcutaneous administration is preferred except in
patients with severe cardiac iron deposition, for whom continuous intravenous deferoxamine
therapy is recommended. Iron excretion occurs through biliary and urinary routes [29].
Adverse events of DFO include growth retardation, skeletal changes, ocular and auditory
disturbances, pulmonary, and renal toxicities. They are preventable if proper monitoring is
practiced to detect early signs of toxicity. Susceptibility to infection with Yersinia and perhaps
other Gram-negative bacilli is increased in thalassemia patients who receive DFO therapy.
Painful local skin reactions at the infusion site are common. Zinc deficiency can occur [29].
7.2.2. Deferiprone
Deferiprone (DFP) is an orally administered bidentate iron chelator (Ferriprox®, Kelfer®). The
usual dose of DFP is 75–100 mg/kg/day taken orally in three divided doses. Plasma half-life of
DFP is 2–3 h, and iron is mainly excreted in urine [30]. Adverse effects of DFP include
gastrointestinal disturbances, agranulocytosis and neutropenia, arthropathy, increased liver
enzyme levels, and low plasma zinc level [29, 30].
7.2.3. Deferasirox
Deferasirox (DFX) is an orally administered tridentate iron chelator that is indicated for the
treatment of transfusion iron overload in persons more than 2 years of age. The US Food and
Drug Administration approves a recommended daily dose of 20–40 mg/kg body weight, taken
once on an empty stomach at least 30 min before food [29]. The most common adverse events
with DFX therapy include gastrointestinal disturbances, rash, and mild increases in serum
creatinine [31].
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7.2.4. Combination therapy
1. “Shuttle hypothesis”: combination of DFO and deferiprone
Combined DFO and DFP regimens offer an alternative option for patients with severe
heart disease. Deferiprone, though a weaker chelator, is a relatively small uncharged mole-
cule that can enter the cardiac cells more easily than DFO and transfers the chelated iron
from the myocardial cells to the stronger chelator, DFO in the plasma [32].
2. Combination of Deferasirox and DFO
The efficacy of combining DFO with Deferasirox has been assessed in a number of studies.
This combination has an additive effect, allows decreasing the dose of both chelators and
improves the compliance. The “shuttle effect” is also applicable with this combination as
Deferasirox acts as an intracellular chelator and DFO as a powerful extracellular chelator
[32].
7.3. Splenectomy
Splenectomy is recommended when the calculated annual transfusion requirement is >200 to
220 ml RBCs/kg per year with a hematocrit of 70%. Splenectomy may be necessary to decrease
the disabling effects of abdominal pressure and to increase the life span of supplemental RBCs.
After splenectomy, children generally require fewer transfusions, although the basic defect in
Hb synthesis remains unaffected. Splenectomy is a therapy that should not be considered
casually because susceptibility to infection with Streptococcus pneumoniae, Haemophilus
influenza, and Neisseria meningitids increases after splenectomy in children, particularly in those
younger than 5 years. Standard therapy for splenectomized individuals includes immuniza-
tions, prophylactic penicillin, and a high index of suspicion and aggressive antibiotic therapy
for febrile illness. Thromboembolic events and pulmonary hypertension are also increased in
splenectomized patients. These complications may be minimized by the routine use of aspirin
or low dose anticoagulants [28].
7.4. Stem cell transplantation (SCT)
SCT or bone marrow transplantation (BMT) is the only possible, proven curative treatment for
β-thalassemia major. The most important role of SCT is the high chance of cure for individuals
who otherwise face a lifetime of invasive, demanding treatment and a reduced life span [33].
7.5. Vitamin supplementation
Vitamin E supplementation in thalassemia major is often suggested, but data demonstrating
its efficacy are lacking. Folic acid supplements help to maintain folic acid levels in the face of
increased requirements [27].
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7.6. Fetal hemoglobin induction
In β-thalassemia, pharmacologically induced increase in γ-globin chains would be expected
to decrease globin chain imbalance with consequent amelioration of clinical manifestation.
Pharmacologically, three classes of agents have been shown to be capable of inducing HbF to
therapeutic levels: erythropoietins, short-chain fatty acid derivatives, and chemotherapeutic
agents. Hydroxyurea has been recommended in patients with thalassemia intermedia [28].
7.7. Gene therapy
B-Thalassemia is a potential attractive target for gene therapy. This could be a reality if a
functional β-globin gene could be safely and efficiently introduced into the hematopoietic stem
cells, and lineage-restricted expression of the β-globin protein exceeding 15% could be
achieved in erythroid progenitor cells. Gene therapy for β-thalassemia requires gene transfer
into hematopoietic stem cells (HSCs) using integrating vectors that direct the regulated
expression of β-globin at therapeutic levels [34].
8. Prevention
Prevention strategies include community education, carrier detection, genetic counseling, and
prenatal diagnosis [27].
9. Conclusion
β-Thalassemias are markedly heterogeneous at their molecular level with a clear association
between genotype and clinical phenotype. Study of the molecular genetics in patients with
β-thalassemia in their early life will serve as a tool to predict clinical disease severity and help
in planning of early intervention strategies.
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